All In Biotech

Drug Trial Radar · NCT00370331

RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag

A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy, Safety and Tolerability of Eltrombopag Olamine (SB-497115-GR), a Thrombopoietin Receptor Agonist, Administered for 6 Months as Oral Tablets Once Daily in Adult Subjects With Previously Treated Chronic ITP.

Last checked: Nov 20, 2026Latest source record: Apr 18, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 197 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

197

Actual

Start

Nov 2006

Primary completion

Jul 2008

Study completion Jul 2008

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Aug 31, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The rationale for this Phase III study is to evaluate the 6 month safety and efficacy of eltrombopag in the treatment of previously treated subjects with chronic ITP. The starting dose of eltrombopag, 50 mg, once daily was selected based upon the observed efficacy, safety and pharmacokinetics in a dose-finding Study (TRA100773). This Phase III study is a randomized, double-blind, placebo-controlled, Phase III study, to evaluate efficacy, safety and tolerability of eltrombopag, initially administered as 50 mg oral tablets once daily for six months in adult subjects with previously treated chronic ITP. Subjects will be randomized 2:1, eltrombopag to placebo, and will be stratified based upon splenectomy status, use of ITP medication at baseline and baseline platelet count less than or equal to 15,000/µL. Subjects will receive study medication for 6 months, during which the dose of study medication may be adjusted based upon individual platelet counts. In addition, subjects may taper off concomitant ITP medications and may receive any rescue treatments as dictated by local standard of care. After discontinuation of study medication, subjects will complete follow-up visits at weeks 1, 2, 4 and months 3 and 6.

Conditions

  • Purpura, Thrombocytopaenic, Idiopathic

Interventions

  • eltrombopagDrug

    Subjects will initiate treatment with either 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.

  • PlaceboDrug

    Subjects will initiate treatment with either 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of RespondersTime frame: Baseline; each on-therapy treatment day; Weeks 10, 14, 18, 22, and 26; and Weeks 1, 2, and 4 post-treatment

Locations

115 sites in 25 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Duarte, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    San Francisco, California

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Hollywood, Florida

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Savannah, Georgia

  • GSK Investigational Site

    Honolulu, Hawaii

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Worcester, Massachusetts

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Buffalo, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Cleveland, Ohio

  • GSK Investigational Site

    Lawton, Oklahoma

  • GSK Investigational Site

    Portland, Oregon

  • GSK Investigational Site

    Willow Grove, Pennsylvania

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Lubbock, Texas

  • GSK Investigational Site

    Lubbock, Texas

  • GSK Investigational Site

    Arlington, Virginia

  • GSK Investigational Site

    Seattle, Washington

  • GSK Investigational Site

    Tacoma, Washington

  • GSK Investigational Site

    Vienna, Austria

  • GSK Investigational Site

    Burnaby, British Columbia, Canada

  • GSK Investigational Site

    St. John's, Newfoundland and Labrador, Canada

  • GSK Investigational Site

    Hamilton, Ontario, Canada

  • GSK Investigational Site

    Weston, Ontario, Canada

  • GSK Investigational Site

    Greenfield Park, Quebec, Canada

  • GSK Investigational Site

    Laval, Quebec, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

  • GSK Investigational Site

    Jiang Su Province, China

  • GSK Investigational Site

    Shanghai, China

  • GSK Investigational Site

    Tianjin, China

  • GSK Investigational Site

    Brno, Czechia

  • GSK Investigational Site

    Hradec Králové, Czechia

Showing 40 of 115 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.